Diploid Growth Serum-Reduced Medium Can Reduce Or Eliminate Serum Use In Human And Animal Vaccine Production

While these difficulties and high industry demands have driven the need to reduce or eliminate serum in vaccine production, the longevity of human diploid cells in culture has posed a critical challenge. Diploid cells have a limited capacity to divide, approximately 40–60 population doublings, before they reach the Hayflick limit and become senescent. This limitation requires the development of a serum-reduced or serum-free medium that supports cell growth without adaptation.

To help vaccine manufacturers using diploid cells meet their production forecasts while reducing production costs and serum use, Thermo Fisher Scientific launched the Gibco™ Diploid Growth Serum-Reduced Medium (SRM) System.* Human diploid cells, including MRC-5, WI-38, KMB-17, and 2BS, and chicken embryo fibroblasts (CEFs) can be used with this system. Once cells are recovered and expanded in Diploid Growth SRM, virus production is seamlessly performed with a simple medium exchange into Diploid Production SFM, without requiring cell washes or supplementation with serum or albumin.